Pemigatinib and infigratinib are FDA-approved for previously treated FGFR2 fusion-positive CCA [62,63] on the basis of phase 2 trials which demonstrated a mPFS of 6.9–7.3 months and an overall response rate (ORR) of 23.1–35.5%, and the former demonstrating a mOS of 21.1 months [61,64,65,66]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.